ANI Pharmaceuticals, Inc.NASDAQ: ANIP

ANI Pharmaceuticals to Present at Upcoming November Investor Conferences

· Issued by ANI Pharmaceuticals, Inc. via GlobeNewswire

Summary by 6ix AI

ANI Pharmaceuticals, a diversified biopharmaceutical company, said President and CEO Nikhil Lalwani and members of its executive leadership team will take part in presentations and fireside chats at two investor conferences in November 2026.

Key details

  • Guggenheim 3rd Annual Healthcare Innovation Conference: Tuesday, November 10, 2026, at 1:30 p.m. ET.
  • 2026 Jefferies Global Healthcare Conference in London: Tuesday, November 17, 2026, at 9:30 a.m. GMT.
  • Live and archived webcasts will be available in the Investors section of ANI's website, under Events and Presentations.

6ix AI wrote this summary from the release below and checked it against the release.

PRINCETON, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will participate in presentations and fireside chats at the following upcoming investor conferences:

EventGuggenheim 3rd Annual Healthcare Innovation Conference
DateTuesday, November 10, 2026
Time1:30 p.m. ET
WebcastClick here
Event2026 Jefferies Global Healthcare Conference in London
DateTuesday, November 17, 2026
Time9:30 a.m. GMT
WebcastClick here

The live and archived webcasts will also be accessible from the Company’s website at www.anipharmaceuticals.com, in the Investors section under Events and Presentations.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit https://www.anipharmaceuticals.com.

Investor Relations:
Irina Koffler, Vice President, Investor Relations
T: 917-734-7387
E: [email protected]

Media Relations:
Argot Partners
T: 212-600-1494
E: [email protected]

SOURCE: ANI Pharmaceuticals, Inc.

View original source (GlobeNewswire)ANI Pharmaceuticals, Inc. on 6ix

In the deck

Story so far

Earlier from ANI Pharmaceuticals

Later from ANI Pharmaceuticals

All ANI Pharmaceuticals news releases